| 51 |
19688040 | Calpain-10 expression is elevated in pancreatic islets from patients with type 2 diabetes. | 2009 Aug 18 |
1 |
| 52 |
17394534 | Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up. | 2008 May |
4 |
| 53 |
17980009 | Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone. | 2008 May |
2 |
| 54 |
18246324 | Too much of a good thing: why it is bad to stimulate the beta cell to secrete insulin. | 2008 Apr |
2 |
| 55 |
18457474 | Therapeutic management, delivery, and postpartum risk assessment and screening in gestational diabetes. | 2008 Mar |
1 |
| 56 |
18793589 | Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes. | 2008 Jul |
1 |
| 57 |
18831351 | Relationship between plasma leptin and plasma insulin levels in type-2 diabetic patients before and after treatment with glibenclamide and glimepiride. | 2008 Jan-Mar |
1 |
| 58 |
17174222 | A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes. | 2007 Jan |
1 |
| 59 |
17316868 | Sulfonylurea and glinide reduce insulin content, functional expression of K(ATP) channels, and accelerate apoptotic beta-cell death in the chronic phase. | 2007 Sep |
1 |
| 60 |
17363911 | Comparison of glyburide and insulin for the management of gestational diabetics with markedly elevated oral glucose challenge test and fasting hyperglycemia. | 2007 May |
1 |
| 61 |
17385195 | Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-related mortality. | 2007 Sep |
1 |
| 62 |
17596474 | Glyburide for the treatment of gestational diabetes. A critical appraisal. | 2007 Jul |
1 |
| 63 |
17652641 | A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain. | 2007 Sep 25 |
1 |
| 64 |
17728498 | Sulfonylurea therapy in two Korean patients with insulin-treated neonatal diabetes due to heterozygous mutations of the KCNJ11 gene encoding Kir6.2. | 2007 Aug |
1 |
| 65 |
16324923 | Effects of glimepiride and glyburide on glucose counterregulation and recovery from hypoglycemia. | 2006 Jan |
3 |
| 66 |
16380479 | Glibenclamide treatment recruits beta-cell subpopulation into elevated and sustained basal insulin synthetic activity. | 2006 Jan |
1 |
| 67 |
16443858 | Improved prandial glucose control with lower risk of hypoglycemia with nateglinide than with glibenclamide in patients with maturity-onset diabetes of the young type 3. | 2006 Feb |
1 |
| 68 |
16475928 | Towards selective Kir6.2/SUR1 potassium channel openers, medicinal chemistry and therapeutic perspectives. | 2006 |
1 |
| 69 |
16492219 | Effect of the oral hypoglycaemic sulphonylurea glibenclamide, a blocker of ATP-sensitive potassium channels, on walking distance in patients with intermittent claudication. | 2006 Mar |
2 |
| 70 |
16595597 | The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. | 2006 Jun |
1 |
| 71 |
16713429 | Gliclazide protects 3T3L1 adipocytes against insulin resistance induced by hydrogen peroxide with restoration of GLUT4 translocation. | 2006 Jun |
1 |
| 72 |
16738156 | Predictors of glyburide failure in the treatment of gestational diabetes. | 2006 Jun |
1 |
| 73 |
16873786 | An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin. | 2006 Aug |
1 |
| 74 |
17003289 | Actions of glucagon-like peptide-1 on KATP channel-dependent and -independent effects of glucose, sulphonylureas and nateglinide. | 2006 Sep |
1 |
| 75 |
17047922 | Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the KCNJ11 gene. | 2006 Nov |
2 |
| 76 |
17296510 | Diabetes and hypoglycaemia in young children and mutations in the Kir6.2 subunit of the potassium channel: therapeutic consequences. | 2006 Dec |
1 |
| 77 |
15642492 | Effects of prolonged in vitro exposure to sulphonylureas on the function and survival of human islets. | 2005 Jan-Feb |
1 |
| 78 |
15672015 | Insulin and glyburide therapy: dosage, severity level of gestational diabetes, and pregnancy outcome. | 2005 Jan |
1 |
| 79 |
15912128 | Glibenclamide depletes ATP in renal proximal tubular cells by interfering with mitochondrial metabolism. | 2005 Aug |
1 |
| 80 |
14709397 | Protective actions of gliclazide on high insulin-enhanced neutrophil-endothelial cell interactions through inhibition of mitogen activated protein kinase and protein kinase C pathways. | 2004 Jan |
1 |
| 81 |
14715864 | The insulin secretagogues glibenclamide and repaglinide do not influence growth hormone secretion in humans but stimulate glucagon secretion during profound insulin deficiency. | 2004 Jan |
1 |
| 82 |
14746575 | A placebo-controlled crossover study comparing the effects of nateglinide and glibenclamide on postprandial hyperglycaemia and hyperinsulinaemia in patients with type 2 diabetes. | 2004 Mar |
2 |
| 83 |
15133754 | Effects of glipizide GITS and glibenclamide on metabolic control, hepatic glucose production, and insulin secretion in patients with type 2 diabetes. | 2004 May-Jun |
1 |
| 84 |
15133755 | The antidiabetic agent, gliclazide, reduces high insulin-enhanced neutrophil-transendothelial migration through direct effects on the endothelium. | 2004 May-Jun |
1 |
| 85 |
15230648 | Moxifloxacin and glucose homeostasis: a pooled-analysis of the evidence from clinical and postmarketing studies. | 2004 |
1 |
| 86 |
15243303 | Rosiglitazone improves, while Glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. | 2004 Aug |
1 |
| 87 |
15375790 | Hypoglycemic potential of nateglinide versus glyburide in patients with type 2 diabetes mellitus. | 2004 Oct |
1 |
| 88 |
15563963 | Efficacy of glimepiride in type 2 diabetic patients treated with glibenclamide. | 2004 Dec |
1 |
| 89 |
15579757 | Rosiglitazone, but not glyburide, reduces circulating proinsulin and the proinsulin:insulin ratio in type 2 diabetes. | 2004 Dec |
4 |
| 90 |
12542723 | Influence of treatment with acarbose or glibenclamide on insulin sensitivity in type 2 diabetic patients. | 2003 Jan |
3 |
| 91 |
12589230 | Beneficial effects of a glyburide/metformin combination preparation in type 2 diabetes mellitus. | 2003 Feb |
1 |
| 92 |
12606519 | The insulin secretory granule is the major site of K(ATP) channels of the endocrine pancreas. | 2003 Mar |
1 |
| 93 |
12684219 | Glibenclamide inhibits islet carnitine palmitoyltransferase 1 activity, leading to PKC-dependent insulin exocytosis. | 2003 Aug |
3 |
| 94 |
12746761 | Metabolic effects of mealtime insulin lispro in comparison to glibenclamide in early type 2 diabetes. | 2003 Apr |
2 |
| 95 |
12795025 | [Oral antidiabetic therapy and cardiovascular complications: theoretical problem or clinical evidence?]. | 2003 Apr 6 |
1 |
| 96 |
12803736 | The development of an oral antidiabetic combination tablet: design, evaluation and clinical benefits for patients with type 2 diabetes. | 2003 |
1 |
| 97 |
12877648 | Glyburide/metformin tablets: a new therapeutic option for the management of Type 2 diabetes. | 2003 Aug |
1 |
| 98 |
12882841 | Beneficial effects of insulin versus sulphonylurea on insulin secretion and metabolic control in recently diagnosed type 2 diabetic patients. | 2003 Aug |
2 |
| 99 |
12958175 | ATP-sensitive potassium channels induced in liver cells after transfection with insulin cDNA and the GLUT 2 transporter regulate glucose-stimulated insulin secretion. | 2003 Sep |
2 |
| 100 |
14565810 | Efficacy of sulfonylureas with insulin in type 2 diabetes mellitus. | 2003 Nov |
1 |